Sarepta Therapeutics recently refinanced a significant portion of its debt, extending maturities and enhancing financial ...

Solid Biosciences Inc. (NASDAQ:SLDB) develops therapies for neuromuscular and cardiac diseases in the US. In addition, the ...

Department of Health and Human Services Secretary Robert F. Kennedy approved the addition of Duchenne muscular dystrophy and metachromatic ...

Doug Ingram of Sarepta Therapeutics is my pick for the Worst Biopharma CEO of 2025. He was an easy selection, but unlike some ...

Detailed price information for Sarepta Therapeutics (SRPT-Q) from The Globe and Mail including charting and trades.

The Recommended Uniform Screening Panel now includes DMD and MLD, which has implications for firms developing treatments for ...

Becker is a serious, progressive neuromuscular condition that is X-linked, affecting approximately one in 18,000 male ...

A mom was overjoyed when she learned a gene therapy treatment could save her child's life, until she found out no one would cover the $2 million price tag.

A new class of life-saving drugs is helping children who once had no hope. But some carry a price tag of millions for a ...

Detailed price information for Sarepta Therapeutics (SRPT-Q) from The Globe and Mail including charting and trades.

Sarepta Therapeutics, Inc. , the leader in precision genetic medicine for rare diseases, today announced that it has entered into separate, privately negotiated exchange agreements with a limited ...

Average Upside Potential as of December 10: 104.08% ...